AbbVie Patent-Cliff Exposure & CMS Drug Spending Portfolio
AbbVie (North Chicago, IL): 127 reconciled FDA prescription therapies (18.6% 2025 to 2030 cliff risk), $32.24B 2024 CMS Part D & Medicaid spend, and 103 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | North Chicago, IL |
| Reconciled FDA Portfolio Therapies | 127 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 18.6% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $32.24B |
| 2024 Medicare Part D Spend | $21.58B |
| 2024 Medicaid Spend | $10.66B |
| California HCAI SB 17 Filings | 103 WAC filings (max 24.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.